Detalles de la búsqueda
1.
Safety of intra-cerebrospinal fluid chemotherapy in onco-haematological patients: a retrospective analysis of 627 interventions.
J Neurooncol
; 125(2): 351-8, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26342710
2.
First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Y-ibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group.
Haematologica
; 98(10): 1563-70, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23753021
3.
Real-World Outcomes of Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results of a Spanish Expanded Access Program (EAP).
Oncol Ther
; 11(1): 83-96, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36509945
4.
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry.
Cancer Med
; 12(14): 14892-14901, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37212507
5.
Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
Haematologica
; 88(7): 762-8, 2003 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-12857554
Resultados
1 -
5
de 5
1
Próxima >
>>